SENSEX
NIFTY 50
Hang Seng
Taiwan Weighted
MCX GOLD FEB 05
MCX SILVER MAR 05
USD/INR
EUR/INR80.0630

SENSEX
NIFTY 50
NIFTY MIDCAP 100
S&P BSE MIDCAP
Hang Seng
Taiwan Weighted
DAX
Nasdaq
MCX GOLD FEB 05
MCX SILVER MAR 05
MCX CRUDEOIL JAN 19
MCX NATURALGAS JAN 25
USD/INR
EUR/INR
GBP/INR
JPY/INR

Market Highlights: Sensex rallies 834 points, Nifty ends above 14,500 led by metals, banks

Global Markets: Asia shares pare losses as China economy rebounds

Oil prices extend gains after US inventory drop

Wrapping 2020 with a subtle depreciation- What’s on the cards for the Rupee in 2021?

Healthcare

Niti Aayog’s VK Paul says decision to obtain stockpile of vaccine is dependent on licensure status

Updated : November 27, 2020 05:09 PM IST

On the vaccine front, there has been a lot of activity in the past few weeks, with various companies sharing the initial analysis of their trial data. American pharma giants Pfizer and Moderna, and Russia's RDIF have said that their vaccines have shown around 95 percent efficacy during trials. RDIF has also tied up with Hetero Pharma to manufacture Sputnik-V vaccines in India.

Serum Institute, the Indian manufacturing partner for Oxford vaccine, has also said that their vaccine is safe and effective. It has also stated that the Indian trials for the vaccine are running smoothly with strict adherence to all the necessary processes and protocols.

Oxford University and AstraZeneca, which had claimed up to 90 percent efficacy for their vaccine, have acknowledged that some of the vials used in their trial didn't have the right concentration of COVID vaccine so some volunteers got a half dose. But they added that the problem has been corrected -- AstraZeneca is now likely to conduct an additional global trial for its vaccine.

Doctor VK Paul, Member of NITI Aayog and Head, National Task Force on COVID-19, said, “There are exciting developments and we heard about two vaccines moving forward. We are also hearing that these vaccines and some others may also be seeking emergency licensure in their respective countries.”

“As of today there is no licensed vaccine which has crossed phase III satisfactorily with data being more available in the public domain so that is where today we are. We are fortunate that are own Indian vaccine candidate are moving forward satisfactorily.”

He also said, “The decision to obtain a particular stock pile of the vaccine is dependent upon the licensure first and foremost and that is a technical process.”

To know more, watch this video.

You May Also Like

IRFC IPO fully subscribed on Day 2; retail portion booked 1.95 times

IRFC IPO fully subscribed on Day 2; retail portion booked 1.95 times

MEA to provide 8.1 lakh COVAXIN doses for free to these 7 countries

MEA to provide 8.1 lakh COVAXIN doses for free to these 7 countries

Expect to deliver first Tejas Mark-1A aircraft in 36 months from signing contract: HAL

Expect to deliver first Tejas Mark-1A aircraft in 36 months from signing contract: HAL

Trending on CNBC-TV18

Live TV

recommended for you